An article written by the Associated Press confirms that Pfizer has been granted approval by the Food and Drug Administration to update the version of its best-selling infection vaccine which is applied towards infants and children.

The vaccine, Prevnar 13, is build to reduce the risk of infection by 13 strains of pneumococcal disease and protect against six additional strains of bacterial infection compared with the current vaccine. The old vaccine was priced at $80 and the new vaccine will cost an additional 35% to $108. Prevnar 13, developed by Wyeth, is the first product to win FDA approval since Pfizer acquired that company last year for $68 million. With sales ranging $2.7 billion in 2008, Prevnar was the world’s top-selling vaccine in 2008.

Shares of Pfizer trade on the NYSE and are down 0.14 cents or 0.76% trading at 17.68.

Johnson & Johnson (NYSE: JNJ), specializes in the research and development, manufacturing and sale of a wide range of products in the health care field. Johnson & Johnson Chairman and CEO, William C. Weldon, will attend the 7th Annual World Health Care Congress, which will gather top CEO’s and leaders from all aspects of the health care industry to discuss and debate on the business of health care., which will run from April 12th to the 14th. Johnson & Johnson closed the day at 63.28, down 0.17 cents or 0.27%, before trading in the range of 62.52 and 63.35.

GlaxoSmithKline PLC (NYSE: GSK), closed at the day’s high of 37.13, down 0.20 cents or 0.54%, after hitting a low of 36.71. GSK has voluntarily stopped the manufacture, distribution and advertising of all Super PoliGrip denture adhesive products containing zinc. Lawyers at the law firm of Parker Waichman Alonso LLP called for a full recall of GSK’s Super PoliGrip products made with zinc as GSK has allowed the Super PoliGrip products already on store shelves to remain on the market. GlaxoSmithKline PLC is a global healthcare group, engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products.

Bayer AG (OTC: BAYR), shares of BAYR have dropped significantly since its 52 week-high of 81.60 from December 29, 2009. BAYR closed at the day’s high of 67.62, down 0.03 cents or 0.04%, after it touched down on the day’s low of 66.60. The subsidiary of Bayer AG has been sued for an amount exceeding $50 million, by Servcor International, a Florida based consultant in the roofing and construction industry. Servcor alleges that Bayer breached its partnership agreement when it shut Servcor out of a $15 million airport roofing contract. Bayer AG is the management holding company for the Bayer Group. Bayer MaterialScience supplies materials, such as polycarbonates and polyurethanes, and system solutions such as coatings, for a range of everyday uses.

Bristol Myers Squibb Co. (NYSE: BMY), closed the day on a red note today after it traded between 24.20 and 24.55, closing down 0.23 cents or 0.93% at 24.48. Bristol Myers will provide a business update to the investment community on March 4, 2010. A live webcast will be available at http://investor.bms.com. Bristol-Myers is a global biopharmaceutical company focused on the development and delivery of innovative medicines dealing with serious diseases.

About Picksthatmove.com

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies. PicksThatMove.com is not a registered investment advisor or broker-dealer. PicksThatMove.com’s affiliates, offices, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value. Please follow us on Twitter and Facebook for further investment updates. We recommend you do your own Due Diligence before investing in any of the stocks mentioned above.

Bioniche Life Sciences (TSE:BNC) surged 50.00% up to $1.05 on news the Canadian based biopharmaceutical company has met two major milestones under its licensing agreement with Endo Pharmaceuticals: Bioniche will receive royalties totalling US$8 million for rights to their drug therapeutic treatment of non-muscle-invasive bladder cancer, Urocidin, in North America.  Furthermore, Endo Pharmaceuticals will execute its exclusive licence to develop and market the drug worldwide, and Endo will all assume the development expenses for the product. 

In July 2009, Bioniche entered into a venture deal with Endo Pharmaceuticals valued at $20 million, to develop and market the cancer drug.  The terms of the agreement projected additional payments of up to $110 million.

Headquartered in Belleville, Ontario, Bioniche Life Sciences Inc is a technology and research-based biopharmaceutical company conducting research, development and commercialization of biopharmaceuticals for human and animal health, along with projects in food safety. 

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Opko Health Inc. (AMEX:OPK) jumped 21.83% up $2.12 on news the company has developed a simple blood test for Alzheimer’s disease, which assess the levels of antibodies unique to the disease with 95% accuracy. Headquartered in Miami, Florida, Opko Health, Inc., is a specialty healthcare company discovering, developing, and commercializing its proprietary pharmaceuticals, drug delivery technologies, diagnostic systems, and instruments for the treatment, diagnosis, and management of various disorders.

Rexahn Pharmaceuticals, Inc. (AMEX:RNN) rose 16.29% up to $0.919 on no news.  The stock’s intra-day high is sitting at $0.95 and trading above its 200 day moving average of $0.810. Based in Rockville, Maryland, Rexahn Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company which discovers, develops, and commercializes treatments for cancer, central nervous system disorders, sexual dysfunction in the US. The company currently has three drug candidates in Phase II clinical trials which include Serdaxin for the treatment of depression, Archexin for the treatment of renal cell carcinoma and pancreatic cancer; and Zoraxel for the treatment of sexual dysfunction.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Compugen Ltd.  (NASDAQ:CGEN) rose 7.07% up to $ 4.39 on news the company posted narrower losses than expected in their 2009 Q4 results. During the last quarter of 2009 the company benefitted from a partnership with Pfizer to develop their pipeline, and successfully raised capital to further fund discoveries in 2010.  The company made progress and received promising results from studies of in vivo trails for various treatment candidates for cancer and inflammation.  Based in Tel Aviv, Israel, Compugen is a drug company which discovers and commercializes its candidates by early-stage licensing and co-development deals. The company’s business is focused on developing and using predictive computer-based discovery platforms to determine therapeutic drug candidates and diagnostic biomarker candidates. GCEN stock has gained 698% since last February.

Oncolytics Biotech, Inc. (TSE:ONC) jumped 14.95% up to $3.23 on no news; however the company is expected to begin enrolment for its upcoming Phase 3 trial for Reolysin.  Reolysin is being developed as a therapeutic for the treatment of head and neck cancers.  Headquartered in Calgary, Alberta, Oncolytics Biotech, Inc is a biopharmaceutical company which discovers and develops therapeutic products for the treatment of cancer.  The company currently has more than a dozen trials at various stages in the US, UK and Canada for their lead drug candidate Reolysin. The company has a market cap of about $183 million and the financial wherewithal to fund the company through Phase 3 FDA evaluations.  According to Research and Markets the global head and neck cancer market is expected to grow at a rate of 8.3% annually for the next six years to reach $1,809M by 2016.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Western Coal Corp. (TSX: WTN), $3.43, +0.28, 8.89%, is making considerable gains today trading near the day’s high of 3.47 touching down on a low of 3.26.  Western Coal released its operating results for the three and nine month period ending December 31, 2009.  Some key points included consolidated revenues of $118.7 million were 10% higher than fiscal second quarter 2010, attributable to 175,000 tonnes of coal sold at previous coal year prices.  Western Coal also reports that they commenced operations on a permit for Maple Coal surface mine which increases reserves of marketable tons to over 10 million short tons, which is a 67% increase in the Maple surface reserves.  Western is a producer of high quality metallurgical and thermal coal from mines located in northeast British Columbia and West Virginia.

Arco Resources Corp. (TSXV: ARR), $0.06, +0.015, 33.33%, is trading in a tight spread between 0.045 and 0.07, coming close to reaching its 52 week-high of 0.075.  The company holds a 100% interest in six mineral claim blocks in Oaxaca, Mexico.  Arco reported on its underground sampling program from its 386 hectare Taviche property.  The results showed a 230 metre long shoot of the vein with silver-gold values averaging 173 g/t silver (Ag) and 1.5 g/t gold (Au).  Other samplings identified a similar 220 metre long shoot averaging 161 g/t Ag and 2.18 g/t Au.  The Tavish vein is a silver-gold-bearing quartz vein.

Rexahn Pharmaceuticals Inc. (AMEX: RNN), $0.76, +0.07, 10.14%, is a clinical stage pharmaceutical company focused on treatments of cancer, CNS disorders, sexual dysfunction and other medical needs.  The company has three drug candidates in Phase II clinical trials, Archexin™, Serdaxin™ and Zoraxel™.  RNN has been trading today between the 0.68 and 0.825 range on gains of over 10%.  Rexahn is presenting today at the 12th Annual BIO CEO & Investor Conference.  Rexhan’s Chairman and CEO, Dr. Chang H. Ahn, will speak about a business overview and provide updates on Rexahn’s recent clinical and financing milestones.

Cord Blood America Inc. (OTCBB: CBAI), $0.01, +0.001, 11.11%, is trading the day away in the range of 0.009 and 0.011, with the 52 week-high sitting at 0.02.  Cord Blood announced yesterday that it has finalized an agreement to process and store cord blood specimens for BioCells, Inc.  BioCells is the second largest stem cell storage company in Argentina with annual revenues of 1.5M (USD) and 12 locations throughout that country.  Cord Blood America facilitates umbilical cord blood stem cell preservation for expectant parents and their children.

Cell Therapeutics Inc. (NASDAQ: CTIC), $0.78, +0.14, 21.88%, focuses on the development, acquisition and commercialization of drugs for the treatment of cancer.  On February 11, 2010, the Cell Therapeutic’s team will host a conference call to review the Company’s 2009 fourth quarter and year-end achievements and financial results.  Cell Therapeutics is trading between 0.74 and 0.80, with its 52 week-high sitting at 2.23.

About Picksthatmove.com

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies. PicksThatMove.com is not a registered investment advisor or broker-dealer. PicksThatMove.com’s affiliates, offices, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  Please follow us on Twitter and Facebook for further investment updates.  We recommend you do your own Due Diligence before investing in any of the stocks mentioned above.

CombinatoRx, Incorporated (NASDAQ:CRXX) rose 11.22% up to $1.19 on news; however the company expects an answer on February 22nd from the FDA regarding a review of the New Drug Application for Neuromed’s drug candidate Exalgo for pain management.  CRXX is trading above its 200 day moving average of $1.06.  Based in Cambridge, Massachusetts, CombinatoRx, Inc., is a biopharmaceutical company which discovers, develops, and out-licenses combination pharmaceuticals created by blending drugs to treat various diseases, cancer, metabolic diseases, inherited diseases, and other medical conditions.

OXiGENE, Inc. (NASDAQ:OXGN) gained 10.81% up to $1.23 on no news. Headquartered in Waltham, Massachusetts, OXiGENE, Inc., is a biopharmaceutical company developing small-molecule therapeutics to treat cancer and eye diseases in the US. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumour progression and visual impairment in ocular diseases

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

La Jolla Pharmaceutical Company (NASDAQ:LJPC) advanced 23.36% up to $0.1360 on no news; however the biopharmaceutical company announced this week it expects that NASDAQ will take action to begin proceedings to delist the company’s common stock. Based in San Diego, California La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery and development of small molecule therapy for the treatment of autoimmune diseases, and acute and chronic inflammatory disorders and acute and chronic inflammatory disorders such as Lupus.

CombinatoRx, Incorporated (NASDAQ:CRXX) rose 14.02% up to $1.22 on no news since the company announced changes to its senior management team following its merger with Neuromed.  The company expects news on February 22nd from the FDA regarding a review of the New Drug Application for Neuromed’s drug candidate Exalgo for pain management.  CRXX is surging on heavy volume and trading above its 200 day moving average of $1.05.  Based in Cambridge, Massachusetts, CombinatoRx, Inc., is a biopharmaceutical company which discovers, develops, and out-licenses combination pharmaceuticals created by blending drugs to treat various diseases, cancer, metabolic diseases, inherited diseases, and other medical conditions.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Cortex Pharmaceuticals (AMEX:CORX) gained 20.00% up to $0.12 on news the company announced a private placement of $1.5 million in a promissory note by Samyang Optics Co., Ltd. The note accrues interest at the rate of 6% per annum and may be converted into Cortex’s common stock at Samyang’s option at any time after April 15, 2010 and if not converted may be subject to repayment at its maturity date on January 15, 2011. The number of common shares issuable upon conversion of the note shall be based upon the greater of market price per share at closing or a 15% discount to the market price of the common stock at the conversion date. Based in Irvine, California, Cortex Pharmaceuticals, Inc. discovers, develops, and commercializes pharmaceuticals for the treatment of neurological and psychiatric disorders.

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) rose 15.36% up to $2.21 on no news. Based in Petaluma, California, Oculus Innovative Sciences is a biopharmaceutical company which develops, manufactures and markets products based upon Microcyn Technology platform, including formulations designed to significantly reduce the need for antibiotics to fight infections.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Antigenics, Inc. (NASDAQ:AGEN) rose 40.40% up to $1.09 with 7,445,439 shares moving on no news in early afternoon trading.  Headquartered in Lexington, Massachusetts the biotechnology company develops cancer vaccines and other treatments for cancer and infectious diseases.

Pharmacyclics, Inc. (NASDAQ:PCYC) gained 19.66% up to $4.20, to a 52 week high on no news; and up 635% since last February when the stock was trading at a low of $0.57. Headquartered in Sunnyvale, California, Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company which develops and commercializes small-molecule drugs for the treatment of auto-immune diseases and cancer. The company’s products in clinical development include HDAC Inhibitor for advanced solid tumours, recurrent lymphomas, and sarcoma; Btk Inhibitors for the treatment of lymphoma and auto-immune diseases; Factor VIIa Inhibitor for pancreatic cancer; and Motexafin Gadolinium for brain cancer.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Icagen, Inc. (NASDAQ:ICGN) advanced 44.93% up to $1.00 on news the company’s executive management is participating at the 28th Annual JP Morgan Healthcare Conference this week at the Westin St. Francis Hotel in San Francisco.  Management is scheduled to present an overview of its research and development programs at 11:30 a.m. Pacific Time on Thursday, January 14th. The company currently has clinical stage programs for two drug candidates for the treatment of epilepsy, asthma, and inflammation and pain control. Based in Research Triangle Park, North Carolina, Icagen, Inc. is a biopharmaceutical company committed to the discovery, development and commercialization small molecule drugs.     

CombinatoRx, Incorporated (NASDAQ:CRXX) rose 23.44% up to $1.00 at midday on no news, since the company announced changes to its senior management team following its merger with Neuromed.  The company expects news on February 22nd from the FDA regarding a review of the New Drug Application for Neuromed’s drug candidate Exalgo for pain management.  Based in Cambridge, Massachusetts, CombinatoRx, Inc., is a biopharmaceutical company which discovers, develops, and out-licenses combination pharmaceuticals created by blending drugs to treat various diseases, cancer, metabolic diseases, inherited diseases, and other medical conditions.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter